Tarlatamab DeLLphi-304 Phase III ES-SCLC — PatSnap Eureka
Tarlatamab DeLLphi-304: First-Line ES-SCLC Phase III vs. Atezolizumab/Chemo
DeLLphi-304 is testing whether tarlatamab — Amgen's DLL3×CD3 bispecific T-cell engager — can improve on the atezolizumab plus carboplatin-etoposide standard in extensive-stage small cell lung cancer. Explore the trial rationale, competitive landscape, and patent intelligence with PatSnap Eureka.
DeLLphi-304: The Phase III Induction Readout in First-Line ES-SCLC
DeLLphi-304 is a Phase III randomised controlled trial evaluating tarlatamab as a first-line induction or maintenance strategy in extensive-stage small cell lung cancer (ES-SCLC), compared against the current standard of care: atezolizumab combined with carboplatin and etoposide chemotherapy. The trial is designed to assess whether adding or substituting tarlatamab improves outcomes such as overall survival and progression-free survival in the first-line setting.
Tarlatamab is a bispecific T-cell engager (BiTE) antibody developed by Amgen that targets DLL3, a protein highly expressed on small cell lung cancer cells, and CD3 on T cells. By bridging tumour cells and cytotoxic T cells, it redirects immune killing specifically toward DLL3-expressing cancer cells. In ES-SCLC, where DLL3 is overexpressed in the majority of tumours, tarlatamab offers a mechanism distinct from conventional checkpoint inhibition approaches tracked on PatSnap.
The current standard of care — atezolizumab plus carboplatin and etoposide — is based on the IMpower133 trial results. Despite checkpoint inhibitor additions, median overall survival remains approximately 12–13 months, underscoring the high unmet need in this disease. DeLLphi-304 represents the most significant attempt yet to challenge this benchmark with a bispecific immunotherapy approach.
Why DLL3 Is a Compelling Target in SCLC
DLL3's restricted tumour expression profile and high prevalence in SCLC make it one of the most clinically validated targets in thoracic oncology.
DLL3: A Notch Ligand Aberrantly Expressed on SCLC Cells
DLL3 is a Notch ligand that is aberrantly expressed on the surface of small cell lung cancer cells and other high-grade neuroendocrine tumours, but has minimal expression on normal adult tissues. This restricted expression profile makes DLL3 an attractive tumour-associated antigen for targeted therapies.
Minimal normal tissue expressionDLL3 Positivity in Over 80% of SCLC Tumour Samples
Studies have shown DLL3 positivity in over 80% of SCLC tumour samples, providing a broad patient population that could potentially benefit from DLL3-directed agents like tarlatamab. This high prevalence reduces the need for restrictive biomarker selection.
>80% DLL3+ prevalenceBiTE Redirects Cytotoxic T Cells to DLL3-Positive Tumour Cells
Tarlatamab's bispecific design simultaneously engages DLL3 on tumour cells and CD3 on T cells, forming an immunological synapse that redirects cytotoxic killing. This mechanism is orthogonal to PD-L1/PD-1 checkpoint inhibition, offering potential for combination or sequential strategies.
Orthogonal to checkpoint inhibitionMedian OS of 12–13 Months on Current Standard — Improvement Urgently Needed
Despite the addition of atezolizumab or durvalumab to platinum-etoposide chemotherapy, median overall survival in first-line ES-SCLC remains approximately 12–13 months. The disease continues to carry one of the worst prognoses in thoracic oncology, driving the clinical urgency behind DeLLphi-304.
High unmet medical needTarlatamab Clinical & Biomarker Data at a Glance
Key metrics from published DeLLphi-301 Phase II results and SCLC biomarker analyses, synthesised via PatSnap Eureka.
DLL3 Expression Prevalence in SCLC Tumours
Over 80% of SCLC tumour samples express DLL3, defining a broad addressable population for tarlatamab therapy.
DeLLphi-301 Phase II Efficacy vs. SoC OS Benchmark
Tarlatamab 10 mg achieved ~40% ORR and >9-month median DoR in previously treated SCLC, against a first-line SoC OS benchmark of 12–13 months.
First-Line ES-SCLC Treatment Landscape: Key Regimens & Mechanisms
How DeLLphi-304's tarlatamab arm compares to established and emerging first-line strategies, as tracked across patent filings and clinical registrations via PatSnap Analytics.
| Regimen / Agent | Mechanism | Trial / Basis | Median OS (First-Line) | Status |
|---|---|---|---|---|
| Atezolizumab + Carbo/Etoposide | Anti-PD-L1 + Platinum-doublet | IMpower133 | 12.3 months | Approved (SoC) |
| Durvalumab + Platinum-Etoposide | Anti-PD-L1 + Platinum-doublet | CASPIAN | 13.0 months | Approved (SoC) |
| Tarlatamab (DeLLphi-304) | DLL3×CD3 Bispecific T-cell Engager | DeLLphi-304 (Phase III ongoing) | TBD (Phase III primary endpoint) | Phase III Active |
Track Every SCLC Bispecific Patent Filing in Real Time
PatSnap Eureka monitors 120+ patent offices and links filings to clinical programmes automatically.
What DeLLphi-304 Means for the SCLC Treatment Paradigm
Key strategic implications for R&D teams, IP professionals, and oncology researchers tracking the tarlatamab programme.
First Bispecific to Challenge Checkpoint + Chemo SoC in First-Line SCLC
DeLLphi-304 is the first Phase III trial to directly test a bispecific T-cell engager against the established atezolizumab-chemotherapy backbone in the first-line setting. A positive readout would mark a paradigm shift in how the disease is managed from diagnosis.
FDA Accelerated Approval in R/R Setting Validates the DLL3 Target
The 2024 FDA accelerated approval of tarlatamab for relapsed/refractory SCLC — based on DeLLphi-301 Phase II data showing approximately 40% ORR and greater than 9-month median duration of response — provides strong regulatory and clinical validation ahead of the Phase III readout.
How R&D Teams Are Using Eureka to Track Tarlatamab and ES-SCLC
PatSnap Eureka is an AI-powered innovation intelligence platform that aggregates patent filings, clinical trial registrations, regulatory submissions, and scientific literature into a single searchable interface. Researchers and R&D teams can use Eureka to monitor tarlatamab patent landscapes, track DeLLphi-304 trial updates, identify competing bispecific antibody programmes in SCLC, and surface emerging DLL3-targeting technologies — all in real time without manual database searches.
For life sciences teams working in thoracic oncology, Eureka provides direct access to over 2 billion data points across 120+ countries, enabling rapid freedom-to-operate assessments, competitive landscape mapping, and clinical trial intelligence that would otherwise require weeks of manual research. The platform is used by 18,000+ innovators globally.
Organisations tracking the ES-SCLC space can also leverage PatSnap's open API to integrate DLL3 patent monitoring directly into internal R&D workflows, with automated alerts when new filings or trial registrations match defined search criteria. For enterprise security and compliance requirements, PatSnap's Trust Center details data handling and IP protection standards.
Tarlatamab DeLLphi-304 ES-SCLC — key questions answered
Tarlatamab is a bispecific T-cell engager (BiTE) antibody developed by Amgen that targets DLL3, a protein highly expressed on small cell lung cancer cells, and CD3 on T cells. By bridging tumour cells and cytotoxic T cells, it redirects immune killing specifically toward DLL3-expressing cancer cells. In extensive-stage small cell lung cancer (ES-SCLC), where DLL3 is overexpressed in the majority of tumours, tarlatamab offers a mechanism distinct from conventional checkpoint inhibition.
DeLLphi-304 is a Phase III randomised controlled trial evaluating tarlatamab as a first-line induction or maintenance strategy in extensive-stage small cell lung cancer (ES-SCLC), compared against the current standard of care which includes atezolizumab combined with carboplatin and etoposide chemotherapy. The trial is designed to assess whether adding or substituting tarlatamab improves outcomes such as overall survival and progression-free survival in the first-line setting.
The current standard of care for first-line extensive-stage small cell lung cancer is atezolizumab (an anti-PD-L1 checkpoint inhibitor) combined with carboplatin and etoposide chemotherapy, based on the IMpower133 trial results. Durvalumab plus platinum-etoposide is an alternative approved regimen. Despite checkpoint inhibitor additions, median overall survival remains approximately 12–13 months, underscoring the high unmet need in this disease.
DLL3 is a Notch ligand that is aberrantly expressed on the surface of small cell lung cancer cells and other high-grade neuroendocrine tumours, but has minimal expression on normal adult tissues. This restricted expression profile makes DLL3 an attractive tumour-associated antigen for targeted therapies. Studies have shown DLL3 positivity in over 80% of SCLC tumour samples, providing a broad patient population that could potentially benefit from DLL3-directed agents like tarlatamab.
The DeLLphi-301 Phase II trial evaluated tarlatamab in previously treated SCLC patients and demonstrated an objective response rate of approximately 40% with the 10 mg dose, with a median duration of response exceeding 9 months. These results supported accelerated FDA approval of tarlatamab for relapsed/refractory SCLC in 2024, and formed the rationale for advancing the agent into the first-line Phase III DeLLphi-304 trial.
PatSnap Eureka is an AI-powered innovation intelligence platform that aggregates patent filings, clinical trial registrations, regulatory submissions, and scientific literature into a single searchable interface. Researchers and R&D teams can use Eureka to monitor tarlatamab patent landscapes, track DeLLphi-304 trial updates, identify competing bispecific antibody programmes in SCLC, and surface emerging DLL3-targeting technologies — all in real time without manual database searches.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About TarlatamabAccelerate Your ES-SCLC and Bispecific Research with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D.
References
- Horn L, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer (IMpower133). New England Journal of Medicine, 2018.
- Goldman JW, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN). The Lancet, 2019.
- National Cancer Institute. Small Cell Lung Cancer Treatment (PDQ) — Health Professional Version. NCI, 2024.
- U.S. Food and Drug Administration. FDA Grants Accelerated Approval to Tarlatamab for Extensive-Stage Small Cell Lung Cancer. FDA, 2024.
- ClinicalTrials.gov. DeLLphi-304: A Phase 3 Study of Tarlatamab in Participants With Extensive-Stage Small Cell Lung Cancer. NCT identifier on file.
- Ahn MJ, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer (DeLLphi-301). Presented at ASCO Annual Meeting, 2023.
- PatSnap Analytics — IP and competitive intelligence for life sciences R&D teams. PatSnap, 2024.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform.
PatSnap Eureka searches patents and research to answer instantly.